Mechanism of aspirin-induced asthma

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 52, Issue 6, 1997, Pages 613-619

  Szczeklik, A ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ASTHMA; BRONCHOSPASM; CROSS REACTION; DESENSITIZATION; DRUG INDUCED DISEASE; DRUG MECHANISM; HUMAN; ICOSANOID METABOLISM; MEDIATOR RELEASE; NOTE; PATHOGENESIS; PRIORITY JOURNAL; SKIN TEST;

EID: 0030750140     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.1997.tb01039.x     Document Type: Note

References (76)

1. Samter M, Beers RF. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 1968;68:975-83.
2. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Clinical patterns of hypersensitivity to nonsteroidal antiinflammatory drugs and their pathogenesis. J Allergy Clin Immunol 1977;60:276-84.
3. Hoigne RA, Szczeklik A. Allergic and pseudoallergic reactions associated with nonsteroidal anti-inflammatory drugs. In: Borda IT, Koff RS, editors. NSAIDs: a profile of adverse effects. Philadelphia: Hanley and Belfus, 1992: 157-84.
4. Quiralte J, Blanco C, Castillo R, Delgado J, Carillo T. Intolerance to nonsteroidal antiinflammatory drugs: results of controlled drug challenges in 98 patients. J Allergy Clin Immunol 1996;98:678-85.
5. Stevenson DD. Diagnosis, prevention and treatment of adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs. J Allergy Clin Immunol 1984;74:617-22.
6. Szczeklik A. Aspirin-induced asthma. In: Vane JR, Botting RM, editors. Aspirin and other salicylates, London: Chapman & Hall, 1992:548-75.
7. Picado C, Castillo JA, Montserrat JM, Augusti-Vidal A. Aspirin-intolerance as a precipitating factor of life-threatening attacks of asthma requiring mechanical ventilation. Eur Respir J 1989;2:127-9.
8. Marquette CH, Saulnier F, Leroy O, et al. Long-term prognosis for near-fatal asthma. A 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for near-fatal attack of asthma. Am Rev Respir Dis 1992;146:76-81.
9. Settipane RA, Schrank PJ, Simon RA, Mathison DA, Christiansen SC, Stevenson DD. Prevalence of crosssensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. J Allergy Clin Immunol 1995;96:480-5.
10. Virchow Ch, Szczeklik A, Bianco S, et al. Intolerance to tartrazine in aspirin-induced asthma: results of a multicenter study. Respiration 1988;53:20-3.
11. Bochenek G, Nizankowska E, Szczeklik A. Atopy trait in hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy 1996;51:16-23.
12. Bianco S, Robuschi M, Petrigni G. Aspirin-induced tolerance in aspirin-induced asthma detected by a new challenge technique. IRCS J Med Sci 1977;5:129-30.
13. Patriarca G, Ballioni P, Nucero E. Intranasal treatment with lysine-acetylsalicylate in patients with nasal polyposis. Ann Allergy 1991;67:588-92.
14. Milewski M, Mastalerz L, Nizankowska E, Szczeklik A. Standardization of nasal provocation test with lysineaspirin for diagnosis of aspirin intolerance in asthma. Allergy Clin Immunol News 1994;(Suppl 2):156.
15. Schlumberger HD. Drug-induced pseudo-allergic syndrome as exemplified by acetylsalicylic acid intolerance. In: Dukor P, Kallos P, Schlumberger HD, West GB, editors. Pseudo-allergic reactions. Involvement of drugs and chemicals. Basel: Karger, 1980:125-203.
16. Dahlen B, Boreus LO, Anderson P, Andersen R, Zetterström O. Plasma acetylsalicylic acid and salicylic acid levels during aspirin provocation in aspirin-sensitive subjects. Allergy 1994;49:43-9.
17. Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 1990;3:588-93.
18. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971;231:232-4.
19. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. BMJ 1975;1:67-9.
20. Stevenson DD, Lewis RA. Proposed mechanisms of aspirin sensitivity reactions. J Allergy Clin Immunol 1987;80: 788-90.
21. Lee TH. Mechanism of aspirin sensitivity. Am Rev Respir Dis 1992;145:34-36.
22. Bazan N, Bolting J, Vane JR. New targets in inflammation. Inhibitors of COX-2 or adhesion molecules. Dordrecht: Kluwer and William Harvey Press, 1996.
23. Mitchell JA, Belvisi MG, Akarasereenont PD, et al. Induction of cyclooxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br J Pharmacol 1994;113:1008-14.
24. Newton R, Kuitert LM, Slater DM, Adcock IM, Barnes PJ. Cytokine induction of cytosolic phospholipase A2 and cyclooxygenase-2 mRNA is suppressed by glucocorticoids in human epithelial cells. Life Sci 1997;60:67-78.
25. Nasser SMS, Pfister R, Christie PE, et al. Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Am J Respir Crit Care Med 1996;153: 90-6.
26. 4 synthase in aspirinintolerant asthmatic bronchial biopsies. Int Arch Allergy Immunol 1997 (in press).
27. Bianco S, Robuschi M, Petrigni G, et al. Efficacy and tolerability of nimesulide in asthmatic patients intolerant to aspirin. Drugs 1993;46 Suppl 1:115-20.
28. Busse WW. The role of leukotrienes in asthma and allergic rhinitis. Clin Exp Allergy 1996;26:868-79.
29. Sampson AP. The leukotrienes: mediators of chronic inflammation in asthma. Clin Exp Allergy 1996;26: 995-1004.
30. 4 in bronchial asthma. Eur Respir J 1992;5:693-9.
31. 4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991;143:1025-9.
32. 4 and histamine in asthmatics. Am Rev Respir Dis 1992;146:96-103.
33. Sladek K, Szczeklik A. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur Respir J 1993;6:391-9.
34. Ortolani C, Mirone C, Fontana A, et al. Study of mediators of anaphylaxis in nasal wash fluids after aspirin and sodium metabisulfite nasal provocation in intolerant rhinitic patients. Ann Allergy 1987;59:106-12.
35. Ferreri NR, Howland WC, Stevenson DD, Spiegelberg HL. Release of leukotrienes, prostaglandins and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am Rev Respir Dis 1988;137:847-54.
36. Picado C, Ramis I, Rosello J, et al. Release of peptidoleukotrienes into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. Am Rev Respir Dis 1992;145:65-9.
37. Kowalski ML, Sliwinska-Kowalska M, Igarashi Y, et al. Nasal secretions in response to acetylsalicylic acid. J Allergy Clin Immunol 1993;91:580-98.
38. Sladek K, Dworski R, Soja J, et al. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med 1994;149:940-6.
39. 4 synthase: organization, nucleotide sequence and chromosomal localization to 5q35. J Biol Chem 1996;271:11356-61.
40. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991; 144:957-8.
41. Dahlen B, Margolskee DJ, Zetterström O, Dahlen S-E. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax 1993;48:1205-10.
42. Fischer AR, Rosenberg MA, Lilly CM, et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 1994;94:1046-56.
43. Yamamoto H, Nagata M, Kuramitsu K, et al. Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. Am J Respir Crit Care Med 1994;150:254-7.
44. Szczeklik A, Serwonska M. Inhibition of idiosyncratic reactions to aspirin in asthmatic patients by clemastine. Thorax 1979;34:654-7.
45. Philips GD, Ford R, Holgate ST. Inhaled lysine-aspirin as a bronchoprovocation procedure in aspirin-sensitive asthma: its repeatability, absence of a late-phase reaction and the role of histamine. J Allergy Clin Immunol 1989;84:232-41.
46. Dahlen S-E, Nizankowska E, Dahlen B, et al. The SwedishPolish treatment study with the 5-lipoxygenase inhibitor Zileuton in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1995;151:A376.
47. Kuna P, Malmström K, Dahlen S-E, et al. Montelukast (MK-0476), a cys-LT1 receptor antagonist, improves asthma control in aspirin-intolerant asthmatic patients. Am J Respir Crit Care Med 1997 (in press).
48. Sestini P, Pieroni MG, Refini RM, et al. Time-limited protective effect of inhaled frusemide against aspirininduced bronchoconstriction in aspirin-sensitive asthmatics. Eur Respir J 1994;7:1825-9.
49. Bianco S, Pieroni MG, Refini RM, Robuschi M, Vaghi A, Sestini P. Inhaled loop diuretics as potential new antiasthmatic drugs. Eur Respir J 1993;6:130-4.
50. Kowalski ML, Grzegorczyk J, Wojciechowska B, Poniatowska M. Intranasal challenge with aspirin induces cell influx and activation of eosinophils and mast cells in nasal secretions of ASA-sensitive patients. Clin Exp Allergy 1996;26:807-14.
51. 2 measurement in nasal secretions is not a reliable marker for mast cell activation in atopic patients. Clin Exp Allergy 1995;25:1228-34.
52. Szczeklik A, Sladek K, Dworski R, et al. Bronchial aspirin challenge causes specific eicosanoid response in aspirin sensitive asthmatics. Am J Respir Crit Care Med 1996;154: 1608-14.
53. 4 increases in bronchoalveolar lavage fluid (BALF) of aspirin-intolerant asthmatics (AIA) after instillation of indomethacin. J Allergy Clin Immunol 1995;95:170.
54. Kowalski ML, Grzelewska-Rzymowska I, Rozniecki J, Szmidt M. Aspirin tolerance induced in aspirin-sensitive asthmatics. Allergy 1984;39:171-8.
55. Stevenson DD, Hankammer MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis asthma. Long-term outcomes. J Allergy Clin Immunol 1996;98: 751-8.
56. 4 in subjects with aspirin-induced asthma. Am Rev Respir Dis 1989;140: 148-53.
57. 4 production after aspirin desensitization. J Allergy Clin Immunol 1995;96: 148-56.
58. 4 concentrations in aspirin-sensitive asthma. Am J Respir Crit Care Med 1995; 151:1326-30.
59. Szczeklik A. Aspirin-induced asthma as a viral disease. Clin Allergy 1988;18:15-20.
60. Szczeklik A. Prostaglandin E and aspirin-induced asthma. Lancet 1995;345:1056.
61. Pavord ID, Tattersfield AE. Bronchoprotective role for endogenous prostaglandin E2. Lancet 1995;345:436-8.
62. Kuehl FA, Dougherty WH, Ham EA. Interactions between prostaglandins and leukotrienes. Biochem Pharmacol 1984; 33:1-5.
63. 2 mechanism. J Immunol 1993;151:2096-2104.
64. Tenor H, Hatzelmann A, Church MK, Schudt C, Shute JK. Effects of theophylline and rolipram on leukotriene C4 synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol 1996;118: 1727-35.
65. Szczeklik A, Mastalerz L, Nizankowska E, Cmiel A. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am J Respir Crit Care Med 1996;153:567-71.
66. 2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 1996;153:572-5.
67. Chan S, Henderson WR, Shi-Hua Li, Hanifin JM. Prostaglandin E2 control of T-cell cytokine production is functionally related to the reduced lymphocyte proliferation in atopic dermatitis. J Allergy Clin Immunol 1996;97: 85-94.
68. 2 in human bronchi. Am J Respir Crit Care Med 1996;154:244-6.
69. Kahn RM, Okanlami DA, Jacoby DB, Fryer AD. Viral infection induced dependence of neuronal M2 muscarinic receptors on cyclooxygenase in guinea pig lungs. J Clin Invest 1996;98:299-307.
70. Kawabori S, Denburg JA, Schwartz LB, et al. Histochemical and immunohistochemical characteristics of mast cells in nasal polyps. Am J Respir Cell Mol Biol 1992;6: 37-43.
71. Hamilos DL, Leung DYM, Wood R, et al. Eosinophil infiltration in nonallergic chronic hyperplastic sinusitis with nasal polyposis (CHSINP) is associated with endothelial VCAM-1 upregulation and expression of TNF-α. Am J Respir Cell Mol Biol 1996;15:443-50.
72. Dekker JW, Nizankowska E, Schmitz-Schumann M, et al. Aspirin-induced asthma and HLA-DRB1 and HLA-DPB1 genotypes. Clin Exp Allergy 1997 (in press).
73. Lympany PA, Welsh KI, Christie PE, Schmitz-Schumann M, Kemeny DM, Lee TH. An analysis with sequence-specific oligonucleotide probes of the association between aspirininduced asthma and antigens of the HLA system. J Allergy Clin Immunol 1993;92:114-23.
74. Lasalle P, Delneste Y, Gosset P, Grass-Masse H, Wallaert B, Tonnel AB. T and B cell immune response to a 55-kDa endothelial cell-derived antigen in severe asthma. Eur J Immunol 1993;23:796-803.
75. Szczeklik A, Nizankowska E, Serafin A, Dyczek A, Duplaga M, Musial J. Autoimmune phenomena in bronchial asthma with special reference to aspirin intolerance. Am J Respir Crit Care Med 1995;152:1753-6.
76. Szczeklik A, Schmitz-Schumann M, Nizankowska E, Milewski M, Roehlig F, Virchow C. Altered distribution of IgG subclasses in aspirin-induced asthma: high IgG4, low IgG1. Clin Exp Allergy 1992;22:283-7.